Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Elicio Therapeutics ( (ELTX) ) just unveiled an announcement.
On August 12, 2025, Elicio Therapeutics announced the publication of follow-up data from its Phase 1 AMPLIFY-201 study in Nature Medicine, highlighting significant improvements in overall survival and relapse-free survival for patients treated with ELI-002. The study demonstrated a 77% reduction in the risk of death and an 88% reduction in the risk of relapse for patients with T cell responses above the efficacy threshold, indicating the potential of ELI-002 as a transformative treatment for mKRAS-driven tumors.
The most recent analyst rating on (ELTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Elicio Therapeutics stock, see the ELTX Stock Forecast page.
Spark’s Take on ELTX Stock
According to Spark, TipRanks’ AI Analyst, ELTX is a Underperform.
Elicio Therapeutics faces significant financial challenges, with negative revenue growth and poor margins being the primary concerns. Technical analysis indicates bearish momentum, while the valuation aspect shows limited appeal. However, recent positive corporate events, such as leadership changes and clinical advancements, provide some optimism for future potential, albeit with high risk.
To see Spark’s full report on ELTX stock, click here.
More about Elicio Therapeutics
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. The company aims to leverage its Amphiphile (AMP) technology to enhance cancer-specific T cell responses, offering off-the-shelf vaccine solutions that promise low cost and rapid availability.
Average Trading Volume: 44,102
Technical Sentiment Signal: Buy
Current Market Cap: $141.3M
For detailed information about ELTX stock, go to TipRanks’ Stock Analysis page.